Skip to main content

LCD L36593: Polysomnography

LCD L36593, Polysomnography, is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2025-03-20 and first in force 2016-06-13. The policy text runs 1,876 words, and its billing and coding article A56995 lists 28 ICD-10-CM codes that support medical necessity for 14 procedure codes. No other contractor publishes a policy with this title.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2025-03-20
Original effective
2016-06-13
Policy text
1,876 words
Covered ICD-10 codes (articles)
28

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L36593
ContractContractorTypeStates
11201Palmetto GBAA and B and HHH MACSC
11301Palmetto GBAA and B and HHH MACVA
11401Palmetto GBAA and B and HHH MACWV
11501Palmetto GBAA and B and HHH MACNC
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10111Palmetto GBAA and B MACAL
10211Palmetto GBAA and B MACGA
10311Palmetto GBAA and B MACTN
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Billing and coding articles A56006 and A56995: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56006 (Billing and Coding: E&M Coding for Oral Surgeons), Billing and Coding A56995 (Billing and Coding: Polysomnography) carry the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A56006: Billing and Coding: E&M Coding for Oral Surgeons (Billing and Coding, effective 2024-01-01)

Covered ICD-10-CM codes
0
0 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
9
Full article
cms.gov record

Procedure codes: 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215.

A56995: Billing and Coding: Polysomnography (Billing and Coding, effective 2024-03-07)

Covered ICD-10-CM codes
28
4 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
14
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A56995
ICD-10-CMDescription (FY2027)
F51.3Sleepwalking [somnambulism]
F51.4Sleep terrors [night terrors]
F51.5Nightmare disorder
G47.10Hypersomnia, unspecified
G47.11Idiopathic hypersomnia with long sleep time
G47.12Idiopathic hypersomnia without long sleep time
G47.30Sleep apnea, unspecified
G47.31Primary central sleep apnea
G47.33Obstructive sleep apnea (adult) (pediatric)
G47.34Idiopathic sleep related nonobstructive alveolar hypoventilation
G47.35Congenital central alveolar hypoventilation syndrome
G47.36Sleep related hypoventilation in conditions classified elsewhere
G47.37Central sleep apnea in conditions classified elsewhere
G47.39Other sleep apnea
G47.411Narcolepsy with cataplexy
G47.419Narcolepsy without cataplexy
G47.421Narcolepsy in conditions classified elsewhere with cataplexy
G47.429Narcolepsy in conditions classified elsewhere without cataplexy
G47.50Parasomnia, unspecified
G47.51Confusional arousals
G47.52REM sleep behavior disorder
G47.53Recurrent isolated sleep paralysis
G47.54Parasomnia in conditions classified elsewhere
G47.59Other parasomnia

Procedure codes: 95782, 95783, 95800, 95801, 95803, 95805, 95806, 95807, 95808, 95810, 95811, G0398 (Home sleep study test (hst) with type ii portable monitor, unattended; minimum of 7 channels: eeg, eog, emg, ecg/heart rate, airflow, respiratory effort and oxygen saturation), G0399 (Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation), G0400 (Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels).

Coverage indications, limitations and medical necessity

This is a limited coverage LCD that requires accreditation for all sleep disorder clinics providing Medicare services.

Sleep studies and polysomnography (PSG) refer to the continuous and simultaneous monitoring and recording of various physiological and pathophysiological parameters of sleep for 6 or more hours with physician review, interpretation and report. The studies are performed to diagnose a variety of sleep disorders and to evaluate a patient's response to therapies such as continuous positive airway pressure (CPAP). PSG is distinguished from sleep studies by the inclusion of sleep staging.

Criteria for coverage of Diagnostic Tests

All reasonable and necessary diagnostic tests performed by sleep disorder clinics (Sleep Disorder Centers or Laboratories for Sleep Related Breathing Disorders) given for the medical conditions listed under Medical Conditions for Which Testing is Covered are covered, when all of the following criteria are met:

• The documentation should be retained in the patient's medical record.

• For a study to be reported as a polysomnogram, sleep must be recorded and staged.

PSG is defined to include, but is not limited to, the following:

• A 1-4 lead electroencephalogram (EEG) to measure global neural encephalographic activity using electrodes placed on the scalp

• Electrooculogram (EOG) to measure eye movements using electrodes placed near the outer canthus of each eye

• A submental electromyogram (EMG) to measure submental electromyographic activity using electrodes placed over the mentalis, submentalis muscle, and/or masseter regions

• Rhythm electrocardiogram (ECG) with 2 or 3 chest leads

• Nasal and/or oral airflow

• Ventilation and respiratory effort by chest-wall and abdominal movement measured using strain gauges, piezoelectric belts, inductive plethysmography, impedance or inductance pneumography, endoesophageal pressure, or by intercostal EMG

• Gas exchange (oxygen saturation (SpO2)) by oximetry, transcutaneous monitoring, or end-tidal gas analysis

• Extremity muscle activity, motor activity-movement using EMG

• Body positions via mercury switches or by direct observation

• Recordings of vibration (frequency and/or volume) may be recorded

• Transcutaneous CO2, esophageal pH, penile tumescence, and bipolar EEG

Sleep studies are performed in a hospital, sleep laboratory or by an Independent Diagnostic Treatment Facility (IDTF) that is supervised by a physician (MD/DO) trained in analyzing and interpreting the recordings and should be attended by a trained technologist. (For exception to the attendance requirement, see the section on sleep apnea below).

Medical Conditions for Which Testing is Covered

Diagnostic testing will only be covered if the patient demonstrates clinical evidence of 1 or more of the following conditions:

1. NARCOLEPSY:

The diagnosis of narcolepsy is usually confirmed by an overnight sleep study (PSG) followed by a multiple sleep latency test (MSLT). MSLT involves several 20-minute nap opportunities offered at 2-hour intervals. MSLT objectively assesses sleep tendency by measuring the number of minutes it takes the patient to fall asleep. Conversely, the maintenance of wakefulness test (MWT) requires the patient to try to stay awake. MSLT is the better test for demonstration of sleep-onset rapid eye movement (REM) periods, a determination that is important in establishing the diagnosis of narcolepsy. To ensure validity, proper interpretation of the MSLT can only be made following a PSG performed on the preceding night.

The following measurements are normally required to diagnose narcolepsy:

• Polysomnographic assessment of the quality and quantity of nighttime sleep;

• Determination of the latency of the REM episode;

• MSLT; and

• The presence of REM-sleep episodes.

Initial PSG and MSLT occasionally fail to identify narcolepsy. Repeat PSG may be indicated:

• if the first study is technically inadequate due to equipment failure;

• if the subject could not sleep or slept for an insufficient amount of time to allow a clinical diagnosis;

• if initiation of therapy or confirmation of the efficacy of prescribed therapy is needed; or

• if the results were inconclusive or ambiguous.

2. SLEEP APNEA:

The diagnosis of sleep apnea may be made using the following modalities:

a. PSG performed in a sleep laboratory; or

b. Unattended home sleep monitoring device of Type II; or

c. Unattended home sleep monitoring device of Type III; or

d. Unattended home sleep monitoring device of Type IV, measuring at least 3 channels.

Sleep apnea may be due to an occlusion of the airway (obstructive apnea), absence of respiratory effort (central sleep apnea) or a combination of these factors (mixed sleep apnea).

Obstructive sleep apnea (OSA) may be caused by 1 of the following:

• Reduced upper airway caliber due to obesity;

• Adenotonsillar hypertrophy;

• Mandibular deficiency;

• Macroglossia;

• Upper airway tumor;

• Excessive pressure across the collapsible segment of the upper airway;

• Activity of the muscles of the upper airway insufficient to maintain patency.

For patients with severe and unambiguous OSA, the initiation of treatment with nasal CPAP may be incorporated into the diagnostic study night. A "split-night" study (initial diagnostic polysomnogram confirming the diagnosis of OSA followed by CPAP titration during PSG on the same night) may be an alternative to 1 full night of diagnostic PSG followed by a second night of titration as long as:

• CPAP titration is carried out for more than 3 hours; and

• PSG or home sleep study (HST) documents that CPAP eliminates or nearly eliminates the respiratory events during REM and non-rapid eye movement (NREM) sleep.

Repeat PSG or HST for diagnosing sleep apnea requires documentation justifying the medical necessity for the repeated test. Repeat PSG may be indicated:

• if the first study is technically inadequate due to equipment failure;

• if the subject could not sleep or slept for an insufficient amount of time to allow a clinical diagnosis;

• if the results were inconclusive or ambiguous; or

• if initiation of therapy or confirmation of the efficacy of prescribed therapy is needed.

Follow-up PSG or HST is not routinely indicated for patients treated with CPAP, whose symptoms continue to be resolved with CPAP treatment. Follow-up PSG may be indicated; however, under the following circumstances:

• After substantial weight loss has occurred in patients on CPAP for treatment of sleep-related breathing disorders to ascertain whether CPAP is still needed at the previously titrated pressure;

• After substantial weight gain has occurred in patients previously treated with CPAP successfully, who are again symptomatic despite the continued use of CPAP, to ascertain whether pressure adjustments are needed; or

• When clinical response is insufficient or when symptoms return despite a good initial response to treatment with CPAP.

3. PARASOMNIA:

Normally, a clinical history, neurologic examination, and routine EEG obtained while the patient is awake and asleep are often sufficient to establish the diagnosis and permit the appropriate treatment of sleep-related epilepsy. In addition, common, uncomplicated, non-injurious parasomnias, such as typical disorders of arousal, nightmares, enuresis, somniloquy, and bruxism can usually be diagnosed by clinical evaluation alone.

PSG is indicated to provide a diagnostic classification or prognosis when both of the following exist:

• When the clinical evaluation and results of standard EEG have ruled out a seizure disorder; and

• In cases that present a history of episodes during sleep that result in harm to the patient or others.

When PSG is performed for the diagnosis of parasomnias, the following measurements are obtained:

• Sleep-scoring channels (EEG, EOG, chin EMG);

• EEG using an expanded bilateral montage;

• EMG for body movements;

• Audiovisual recording; and

• Documented technologist observations.

4. Other Respiratory Disorders: This diagnostic category includes breathing disorders that are not principally defined by obstructive or central apnea/hypopnea or the upper airways resistance syndrome (UARS).

PSG is indicated for patients with neuromuscular disorder and sleep-related symptoms to evaluate symptoms of sleep disorder that are not adequately diagnosed by obtaining a sleep history, assessing sleep hygiene, and reviewing sleep diaries.

PSG and HST are not indicated to diagnose chronic lung disease. Nocturnal hypoxemia in patients with chronic obstructive, restrictive, or reactive lung disease is usually adequately evaluated by oximetry and does not require PSG or HST. However, if the patient’s symptoms suggest a diagnosis of OSA or periodic limb movement disorder (PLMD), indications for PSG are the same as for those disorders in patients without chronic lung disease.

5. Restless Legs Syndrome (RLS) and PLMD: RLS is a neurologic disorder characterized by disagreeable leg sensations that usually occur at rest or before sleep and are alleviated by motor activity. Periodic limb movements are involuntary, stereotypic, repetitive limb movements that may occur during sleep and usually involve the legs and, occasionally, the arms. Periodic limb movements during sleep often accompany RLS. PLMD is a sleep disorder characterized by periodic limb movements that cause frequent arousals and lead to insomnia or excessive daytime sleepiness. The results of PSG studies from patients with severe RLS often show prolonged sleep latencies, decreased sleep efficiency, increased number of awakenings, significant reductions in total sleep time, and decreased amounts of slow-wave sleep. Patients with PLMD often have frequent periodic limb movements that are associated with arousals and awakenings, reduced total sleep time, and decreased sleep efficiency.

PSG is indicated when a diagnosis of PLMD is considered because of complaints by the patient or an observer of repetitive limb movements during sleep and frequent awakenings, fragmented sleep, difficulty maintaining sleep, or excessive daytime sleepiness.

Limitation of Coverage:

Sleep testing performed using an unattended portable monitor (HST) for the diagnosis of OSA must adhere to the guidelines specified in "Clinical Guidelines for the Use of Unattended Portable Monitors in the Diagnosis of OSA in Adult Patients". If discrepancies exist between these guidelines and this LCD, the parameters in this LCD take precedence. HST is covered only for the diagnostic study of OSA and for no other indications.

HSTs may be used in addition to a face-to-face clinical assessment by the treating physician, Epworth Sleepiness Scale, and physical examination to diagnose OSA; specifically, it is intended only for those patients who exhibit clinical signs and symptoms of OSA.

HST is not covered for patients with certain medical comorbidities, including:

• Moderate to severe pulmonary disease (e.g., patients on oxygen or regular bronchodilator use)

• Neuromuscular disease affecting muscles of respiration

• Congestive heart failure

• Suspicion of the presence of other sleep disorders, i.e., narcolepsy, parasomnia, or periodic limb movements of sleep

• other respiratory disorders, impotence, RLS

HST scoring must be performed by an individual certified by the Board of Registered Polysomnographic Technologists (BRPT) as a Registered Polysomnographic Technologist (RPSGT), or equivalent, or by a polysomnographic technician under the supervision of a RPSGT, or equivalent. RPSGTs and polysomnographic technicians must meet the standards for such individuals promulgated by the American Academy of Sleep Medicine Standards for Accreditation of Laboratories for Sleep Related Breathing Disorders, and be licensed or certified by the state in which they practice, if such licensure or certification exists. The laboratory physician must review the entire raw data recording for every patient studied.

PSG, HST and MSLT are not covered in the following situations:

1. For the diagnosis of patients with chronic insomnia.

Snoring and nasal obstructive signs and symptoms are not, in and of themselves, indications for PSG; however, they may be indications of sleep apnea when other findings are also present. Other causes of sleepiness should be ruled out via a sleepiness scale before performing a sleep study.

2. To preoperatively evaluate a patient for laser-assisted uvulopalatopharyngoplasty without clinical evidence that OSA is suspected;

The policy text continues in the CMS record.

Summary of evidence (opening)

N/A

The contractor cites 8 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2016-06-13
Current revision effective
2025-03-20
Last reviewed by the contractor
2025-02-05
MCD version
37

The contractor lists 2 National Coverage Determinations as related: NCD 240.4 Continuous Positive Airway Pressure (CPAP) Therapy For Obstructive Sleep Apnea (OSA), NCD 240.4.1 Sleep Testing for Obstructive Sleep Apnea (OSA). Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Other related documents: A55958 (Article).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L36593 cover?

This is a limited coverage LCD that requires accreditation for all sleep disorder clinics providing Medicare services. The full 1,876-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L36593 apply to?

Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L36593?

The companion billing and coding article A56995 lists 28 ICD-10-CM codes in 4 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L36593?

A denial under LCD L36593 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56995's 28 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.